Compare VPG & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VPG | GYRE |
|---|---|---|
| Founded | 2009 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 552.5M | 573.4M |
| IPO Year | 2010 | 2004 |
| Metric | VPG | GYRE |
|---|---|---|
| Price | $126.19 | $6.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $53.50 | $17.00 |
| AVG Volume (30 Days) | ★ 652.6K | 85.3K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $307,202,000.00 | $275,000.00 |
| Revenue This Year | $7.21 | $19.88 |
| Revenue Next Year | $6.92 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.22 | N/A |
| 52 Week Low | $25.49 | $5.44 |
| 52 Week High | $136.21 | $9.42 |
| Indicator | VPG | GYRE |
|---|---|---|
| Relative Strength Index (RSI) | 76.00 | 42.18 |
| Support Level | $32.38 | N/A |
| Resistance Level | N/A | $8.13 |
| Average True Range (ATR) | 9.99 | 0.30 |
| MACD | 0.85 | -0.02 |
| Stochastic Oscillator | 78.55 | 43.60 |
Vishay Precision Group Inc manufactures and markets sensors and sensor-based measurement systems, as well as specialty resistors and strain gages based on proprietary technology. The company provides precision products and solutions, many of which are designed-in by customers, specializing in the growing markets of stress, force, weight, pressure, and current measurements. The company reports in three product segments: Sensors segment, Weighing Solutions segment, and Measurement Systems segment. It has a business presence in the United States and other countries. It generates the maximum of its revenue from the United States.
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.